The association of Raynaud syndrome with β-blockers: A meta-analysis

Angiology

Volumn 63, Issue 7, 2012, Pages 535-540

  Mohokum, Melvin ^a   Hartmann, Peter ^a   Schlattmann, Peter ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

blockers; blocking drugs; meta analysis; prevalence; Raynaud phenomenon

Indexed keywords

ACEBUTOLOL; ALPRENOLOL; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; CELIPROLOL; ESMOLOL; LABETALOL; METOPROLOL; METOPROLOL TARTRATE; NADOLOL; NEBIVOLOL; OXPRENOLOL; PINDOLOL; PRACTOLOL; PROPRANOLOL; SOTALOL; TIMOLOL;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CONFIDENCE INTERVAL; HUMAN; META ANALYSIS; PREVALENCE; RAYNAUD PHENOMENON; REGRESSION ANALYSIS;

ADRENERGIC BETA-ANTAGONISTS; CROSS-SECTIONAL STUDIES; HUMANS; RAYNAUD DISEASE;

EID: 84866402500     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319711432861     Document Type: Article

References (31)

1. Block JA, Sequeira W. Raynaud's phenomenon. Lancet. 2001 ; 357 (9273). 2042-2048
2. Heidrich H. Functional vascular diseases: Raynaud's syndrome, acrocyanosis and erythromelalgia. Vasa. 2010 ; 39 (1). 33-41
3. Fraenkel L. Raynaud's phenomenon: epidemiology and risk factors. Curr Rheumatol Rep. 2002 ; 4 (2). 123-128
4. Marshall AJ, Roberts CJ, Barritt DW. Raynaud's phenomenon as side effect of beta-blockers in hypertension. Br Med J. 1976 ; 1 (6024). 1498-1499
5. Tarazi RC, Dustan HP. Beta adrenergic blockade in hypertension. Practical and theoretical implications of long-term hemodynamic variations. Am J Cardiol. 1972 ; 29 (5). 633-640
6. Vorburger C. The anti-hypertensive effect of timolol maleate (blocadren) in gradated combination with a diuretic [in German]. Schweiz Med Wochenschr. 1976 ; 106 (43). 1474-1481
7. Richards S. Cutaneous side-effects of beta-adrenergic blockers. Australas J Dermatol. 1985 ; 26 (1). 25-28
8. Bolli P, Waal-Manning HJ, Simpson FO, Seeman HM. Treatment of hypertension with labetalol. N Z Med J. 1977 ; 86 (602). 557-563
9. Hansson L, Karlberg BE, Aberg H, Westerlund A, Jameson S, Henningsen NC. Long-term hypotensive effect of atenolol (ICI 66.082), a new beta-adrenergic blocking agent. Acta Med Scand. 1976 ; 199 (4). 257-261
10. Zahavi I, Chagnac A, Hering R, Davidovich S, Kuritzky A. Prevalence of Raynaud's phenomenon in patients with migraine. Arch Intern Med. 1984 ; 144 (4). 742-744
11. Schwarzer G.
12. Axford AT, Gilchrist L. Propranolol in the treatment of hypertension. Br J Clin Pract. 1971 ; 25 (7). 326-328
13. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002 ; 21 (11). 1539-1558
14. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003 ; 327 (7414). 557-560
15. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986 ; 7 (3). 177-188
16. Schlattmann P Medical Applications of Finite Mixture Models. Berlin Heidelberg: Springer-Verlag ; 2009:
17. Galbraith RF. Graphical display of estimates having differing standard errors. Technometrics. 1988 ; 30 (3). 271-281
18. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997 ; 315 (7109). 629-634
19. Thompson SG. How should meta-regression analyses be undertaken and interpreted. Stat Med. 2002 ; 21 (11). 1559-1573
20. Lumley T. 2009:
21. Schlattmann P. 2008:
22. Zacharias FJ, Cowen KJ, Prestt J, Vickers J, Wall BG. Propranolol in hypertension: a study of long-term therapy, 1964-1970. Am Heart J. 1972 ; 83 (6). 755-761
23. Steiner JA, Cooper R, McPherson K, Riley AJ. Effect of beta-adrenoceptor antagonists on prevalence of peripheral vascular symptoms in hypertensive patients. Br J Clin Pharmacol. 1982 ; 14 (6). 833-837
24. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009 ; 339: b2700
25. Weinrich MC, Maricq HR, Keil JE, McGregor AR, Diat F. Prevalence of Raynaud phenomenon in the adult population of South Carolina. J Clin Epidemiol. 1990 ; 43 (12). 1343-1349
26. De Angelis R, Salaffi F, Grassi W. Raynaud's phenomenon: prevalence in an Italian population sample. Clin Rheumatol. 2006 ; 25 (4). 506-510
27. Suter LG, Murabito JM, Felson DT, Fraenkel L. The incidence and natural history of Raynaud's phenomenon in the community. Arthritis Rheum. 2005 ; 52 (4). 1259-1263
28. Imms FJ, Neame RL, Powis DA. Responses of the cardiovascular system of the rat to noradrenaline infusions and their modification by adrenoceptor blocking agents. Br J Pharmacol. 1977 ; 60 (1). 115-122
29. Chung MS, Gong HS, Baek GH. Prevalence of Raynaud's phenomenon in patients with idiopathic carpal tunnel syndrome. J Bone Joint Surg Br. 1999 ; 81 (6). 1017-1019
30. Maricq HR, Carpentier PH, Weinrich MC, et al. Geographic variation in the prevalence of Raynaud's phenomenon: a 5 region comparison. J Rheumatol. 1997 ; 24 (5). 879-889
31. Hartmann P, Mohokum M, Schlattmann P. 2011: